The Max Foundation and partner NGO Esperantra are pleased to announce they have signed a new MOU that will help patients in Peru gain access to treatment.
Esperantra, a non-profit organization working to reduce cancer mortality in Peru, has generously agreed to partner with The Max Foundation to facilitate the importation of medicines within Max Access Solutions.
“Esperantra and The Max Foundation are a perfect fit together,” said Inés García González, The Max Foundation’s Region Head for Latin America. “Our organizations have similar goals – expanding access to treatment, reducing cancer mortality, etc. – and Esperantra is a well-established organization in Peru with a great track record. We are honored to partner with them.”
Karla Ruiz de Castilla, Esperantra’s Executive Director, said: “It is our pleasure to partner with The Max Foundation and help expand access to treatment for patients in Peru. Together we are improving clinical outcomes and quality of life for people facing cancer.”
Thanks to the partnership with Esperantra, Peru has become the 70th country to have patients enrolled in Max Access Solutions.
The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 28 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.
The Max Foundation is proud to announce it has signed an expanded collaboration agreement with Bristol-Myers Squibb – a committed pharmaceutical partner and member of our humanitarian pact.
The Union for International Cancer Control (UICC) and multiple partners* are establishing the Access to Oncology Medicines (ATOM) Coalition, a new global partnership to increase access to quality-assured essential cancer medicines in low- and lower middle-income countries (LLMICs) and to help countries develop the capacity for their proper use. It is estimated that less than….
The numbers are in! The Max Foundation is thrilled to announce that Spot On CML, our diagnostic collaboration with Fred Hutchinson Cancer Research Center, has provided free testing to 371 patients across 15 countries in its inaugural year.
